The PARP inhibitor alone had a nearly identical effect in the survival of all breast cancer cell lines, and as expected, PAK1 overexpressing and PAK1-amplified breast cancer cells were much more sensitive to PAK inhibition than HCC1419 cells. This evidence concerns the gene PAK1 and breast cancer.